| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | osimertinib (Tagrisso®) |
| Formulation | 40 mg, 80 mg film-coated tablet |
| Reference number | 2969 |
| Indication | Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 05/05/2016 |
| NICE guidance | TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer |
| Commercial arrangement | PAS |